TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26002111
Drug: Primary surgery
Normalized name: Sodium primary phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary surgery (followed by 6 cycles of chemotherapy)
Study: 10220541
Drug: Beta blocker
Normalized name: Beta blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta blocker treatment
Study: 23500609
Drug: No beta
Normalized name: Amidino beta-alanine
DrugBank: Ompenaclid (DB18819)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No beta blocker treatment
Study: 19240703
Drug: Low-volume phosphate
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-volume phosphate solution (75 ml)
Study: 19240703
Drug: Low-volume sulfate
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-volume sulfate solution (equimolar dose)
Study: 19240703
Drug: PEG (polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG (polyethylene glycol) lavage solution (4 liters)
Study: 15545201
Drug: Increased fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased fluid intake (60 ml/kg body weight per day)
Study: 15545201
Drug: Normal fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal fluid intake (30 ml/kg body weight per day)
Study: 11552354
Drug: Exercise therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise therapy (aerobic, dynamic strengthening exercises)
Study: 2441203
Drug: Captopril (CPT)
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Captopril (CPT) 25 mg every 8 hours (t.i.d.)
Study: 2441203
Drug: Digoxin (D)
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Digoxin (D) 0.25 mg once daily
Study: 29624476
Drug: Novel therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel therapies targeting pro-inflammatory pathways (e.g., IL-12/23 axis, IL-6 pathway, Janus Kinase inhibitors)
Study: 29624476
Drug: Therapies modulating
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapies modulating anti-inflammatory pathways (e.g., TGF-β1)
Study: 29624476
Drug: Drugs targeting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drugs targeting leukocyte adhesion and migration (e.g., α4β7 integrins, MAdCAM-1)
Study: 29624476
Drug: Sphingosine-1-phosphate (S1P)
Normalized name: Sphingosine-1-phosphate (S1P) receptor modulators
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sphingosine-1-phosphate (S1P) receptor modulators
Study: 29624476
Drug: Cell therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cell therapies using mesenchymal stem cells or engineered T regs
Study: 27363734
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (InGaAIP laser, 660 nanometer, 40 milliwatts of power, 5 Joules per square centimeter of energy density for 5 seconds each, total energy = 0.6 Joules)
Study: 11973012
Drug: Lamotrigine (maximum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamotrigine (maximum dose of 400 mg)
Study: 10403341
Drug: PM‐YF vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: PM‐YF vaccine
Study: 10403341
Drug: W‐YF vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: W‐YF vaccine (Arilvax)
Study: 2044332
Drug: Flumazenil 10
Normalized name: flumazenil 100 % MISCELL POWDER (GRAM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumazenil 10 mg intravenously
Study: 7016300
Drug: BCG treatment
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG treatment (120 mg intravesically and 5 mg percutaneously, six weekly administrations)
Study: 27683798
Drug: Increased dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased dosing frequency from every 8 weeks to every 4 weeks
Study: 26072416
Drug: Pexa-Vec (JX-594)
Normalized name: B-VEC
DrugBank: Beremagene geperpavec (DB17831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pexa-Vec (JX-594) administered by intratumoral injection at a dose of 1 × 10(8) pfu
Study: 26072416
Drug: Pexa-Vec (JX-594)
Normalized name: B-VEC
DrugBank: Beremagene geperpavec (DB17831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pexa-Vec (JX-594) administered by intratumoral injection at a dose of 1 × 10(9) pfu
Study: 12663290
Drug: Black tea
Normalized name: black tea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Black tea (1250 mL/d, 5 cups each containing 2 g tea leaves in 250 mL boiled water)
Study: 12663290
Drug: Hot water
Normalized name: hot water bottle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hot water (1250 mL/d)
Study: 10859453
Drug: Morphine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine plus MLT (20 mg/day orally in the evening)
Study: 10859453
Drug: Morphine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine plus MLT
Study: 6360110
Drug: 3% acyclovir
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% acyclovir ointment five times a day in combination with alpha-interferon (30 million IU/mL)
Study: 6360110
Drug: 3% acyclovir
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% acyclovir ointment five times a day
Study: 27923864
Drug: Harm Reduction
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Harm Reduction (HR; eight contacts over 12 months with medication use)
Study: 27923864
Drug: Intensive Treatment
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive Treatment (IT; six contacts over 6 months)
Study: 20524974
Drug: Testosterone undecanoate
Normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone undecanoate (TU; 1,000 mg IM at baseline, and after 6 and 18 weeks)
Study: 7823995
Drug: Once-daily trial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily trial of spontaneous breathing
Study: 2079566
Drug: All treatment
Normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All treatment responders (Groups A, B, C)
Study: 90270
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg BAY g 5421 before a 50 g sucrose meal
Study: 25712847
Drug: Chest tube
Normalized name: Kids-Eeze Chest Relief
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chest tube removal when drainage volume <100 ml/day (Control Group - CG)
Study: 21692283
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy of electroacupuncture and acupoint injection
Study: 10731289
Drug: Enoxaparin and
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin and abciximab administration during percutaneous coronary intervention
Study: 10731289
Drug: Abciximab administration
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Abciximab administration
Study: 1571752
Drug: Clomipramine (100-200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomipramine (100-200 mg/day)
Study: 3883503
Drug: Megestrol acetate
Normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Megestrol acetate 40 mg orally, four times daily
Study: 3883503
Drug: Tamoxifen 10
Normalized name: tamoxifen 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen 10 mg orally twice daily
Study: 25486294
Drug: β-alanine (BA)
Normalized name: Alanine
DrugBank: Alanine (DB00160)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: β-alanine (BA) supplementation (3.4 g)
Study: 25486294
Drug: Placebo (PL;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (PL; 5 g maltodextrin)
Study: 22963388
Drug: Oriental Medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oriental Medicine Music Therapy (OMMT)
Study: 22963388
Drug: Control Music
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control Music Therapy (CMT)
Study: 21054464
Drug: Omeprazole, Amoxicillin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole, Amoxicillin, and Clarithromycin (OAC)
Study: 24921211
Drug: Rabeprazole, Amoxicillin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole, Amoxicillin, and Clarithromycin (RAC)
Study: 12160664
Drug: Remacemide hydrochloride
Normalized name: Chlorpromazine Hydrochloride
DrugBank: Remacemide (DB06458)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remacemide hydrochloride (up to 600 mg daily)
Study: 9622282
Drug: Metoprolol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (100 mg o.d.)
Study: 8352673
Drug: Captopril (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (12.5 mg)
Study: 29621293
Drug: Apomorphine (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apomorphine (1.5 mg subcutaneous injection)
Study: 27164988
Drug: Transhiatal approach
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transhiatal approach and D2 total gastrectomy after neoadjuvant chemotherapy (NAC) for AEG patients
Study: 27164988
Drug: D2 gastrectomy
Normalized name: vitamin D2
DrugBank: Ergocalciferol (DB00153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: D2 gastrectomy after neoadjuvant chemotherapy (NAC) for non-AEG patients
Study: 26222764
Drug: Neoadjuvant systemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant systemic therapy (NST) including neoadjuvant paclitaxel ± carboplatin ± bevacizumab followed by doxorubicin plus cyclophosphamide ± bevacizumab
Study: 21048092
Drug: Dopexamine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopexamine (0.5 μg · kg(‐1) · min(‐1))
Study: 17010742
Drug: 1 mg/L
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/L methoxsalen
Study: 17010742
Drug: 5 mg/L
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/L methoxsalen
Study: 14740594
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg bupivacaine 0.1% mixed with 20 micrograms fentanyl
Study: 14740594
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg bupivacaine 0.1%
Study: 19390752
Drug: Megestrol acetate
Normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Megestrol acetate (MA) 800 mg/day
Study: 1441877
Drug: 20 ml
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml of 2.2% lidocaine hydrocarbonate with 5 micrograms.ml‐1 epinephrine (Group CO2 = 13 patients)
Study: 1441877
Drug: 20 ml
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml of 2% lidocaine hydrochloride with 5 micrograms.ml‐1 epinephrine (HCl group)
Study: 27515885
Drug: Kuan-Sin-Yin (KSY)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kuan-Sin-Yin (KSY) herbal decoction, 100 mL daily for 6 weeks
Study: 27515885
Drug: Placebo herbal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo herbal decoction, 100 mL daily for 6 weeks
Study: 14688492
Drug: Pravastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin (40 mg daily)
Study: 9296940
Drug: Intravenous Augmentin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Augmentin 1.2 g
Study: 2691484
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no antibiotic)
Study: 8282140
Drug: Estriol (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estriol (8 mg/day first week, 4 mg/day second and third week, 2 mg/day fourth week)
Study: 20406589
Drug: Coseasonal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coseasonal therapy with 5000 AU/week for 6 weeks
Study: 20406589
Drug: Precoseasonal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Precoseasonal therapy with 3000 AU/week for 10 weeks
Study: 15708385
Drug: Albendazole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albendazole (400 mg, two doses six months apart)
Study: 12592272
Drug: Misoprostol 50
Normalized name: diclofenac-misoprostol 50 mg-200 mcg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misoprostol 50 microg every 6 hours for two doses
Study: 12592272
Drug: Dinoprostone insert
Normalized name: dinoprostone Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dinoprostone insert 10 mg for one dose intravaginally
Study: 12592272
Drug: Dinoprostone gel
Normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dinoprostone gel 0.5 mg every 6 hours for two doses
Study: 17889983
Drug: Dinoprostone gel
Normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dinoprostone gel
Study: 10495374
Drug: Finasteride 0.01
Normalized name: ALFATRADIOL 0.05 g in 100 g / MINOXIDIL SULFATE ESTER 12 g in 100 g / FINASTERIDE 0.01 g in 100 g TOPICAL LIQUID [NR-11]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finasteride 0.01 mg
Study: 10495374
Drug: Finasteride 0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finasteride 0.05 mg
Study: 15319158
Drug: Finasteride 1
Normalized name: finasteride 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finasteride 1 mg
Study: 31065046
Drug: Adjustment for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjustment for homeostasis model assessment of insulin resistance
Study: 23860105
Drug: Padma Digestin
Normalized name: Padma Flower
DrugBank: Nelumbo nucifera flower (DB14333)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Padma Digestin (2 × 3 capsules daily for 6 weeks)
Study: 21865569
Drug: 2 servings
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 servings of vegetables (130 g)
Study: 21865569
Drug: 5 servings
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 servings of vegetables (287 g)
Study: 21865569
Drug: 10 servings
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 servings of vegetables (614 g)
Study: 21865569
Drug: All doses
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All doses of vegetables
Study: 19967149
Drug: Simvastatin 40
Normalized name: simvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 40 mg/day (n = 28)
Study: 11113085
Drug: Pentoxifylline (PTX)
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentoxifylline (PTX) 400 mg orally 3 times daily
Study: 1549966
Drug: Diltiazem CD
Normalized name: Diltiazem Hydrochloride 300 MG Oral Capsule, Extended Release, 24 HR [DILTIAZEM CD]
DrugBank: Diltiazem (DB00343)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diltiazem CD 90 mg
Study: 1549966
Drug: Diltiazem CD
Normalized name: Diltiazem Hydrochloride 300 MG Oral Capsule, Extended Release, 24 HR [DILTIAZEM CD]
DrugBank: Diltiazem (DB00343)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diltiazem CD 180 mg
Study: 1549966
Drug: Diltiazem CD
Normalized name: Diltiazem Hydrochloride 300 MG Oral Capsule, Extended Release, 24 HR [DILTIAZEM CD]
DrugBank: Diltiazem (DB00343)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diltiazem CD 360 mg
Study: 1549966
Drug: Diltiazem CD
Normalized name: Diltiazem Hydrochloride 300 MG Oral Capsule, Extended Release, 24 HR [DILTIAZEM CD]
DrugBank: Diltiazem (DB00343)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diltiazem CD 540 mg
Study: 2421976
Drug: Dextran 70
Normalized name: Dextran 70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextran 70 (0.5 L)
Study: 22659533
Drug: Add-on ezetimibe
Normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Add-on ezetimibe (10 mg/day)
Study: 22659533
Drug: Double-dose pravastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-dose pravastatin
Study: 18589030
Drug: Algal-oil capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Algal-oil capsules (600 mg DHA/day)
Study: 14607455
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (24 mg/min)
Study: 11796586
Drug: Monovalent meningococcal
Normalized name: MENINGOCOCCAL B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monovalent meningococcal B OMV vaccine
Study: 10320158
Drug: Intravenous lactated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous lactated Ringer's solution (LR)
Study: 8916607
Drug: Increase fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increase fluid intake by 500 cc
Study: 8916607
Drug: Decrease fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decrease fluid intake by 300 cc
Study: 1790544
Drug: Nitrendipine 20
Normalized name: nitrendipine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine 20 mg daily for 60 days
Study: 6125089
Drug: Alprazolam (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam (0.75 mg to 3 mg per day, average final dose: 1.59 mg)
Study: 6125089
Drug: Lorazepam (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam (3 mg to 12 mg per day, average final dose: 5.97 mg)
Study: 17727574
Drug: Combination therapies
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapies for refractory cases of NE
Study: 9699022
Drug: Selenium-enriched yeast
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium-enriched yeast supplementation (4.8 mg yeast containing 5 microgram selenium daily via naso-gastric drip for 14 days)
Study: 2506874
Drug: Intralipid 20%
Normalized name: Intralipid 20% Fat Emulsion for Injection
DrugBank: Soybean oil (DB09422)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralipid 20% administered to ten infants
Study: 2506874
Drug: Sunflower seed
Normalized name: SUNFLOWER SEED
DrugBank: Sunflower seed (DB10907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunflower seed oil rubbed six times daily on the skin of nine infants
Study: 2506874
Drug: Intralipid administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralipid administered to four patients who had previously received sunflower seed oil
Study: 2506874
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of sunflower seed oil
Study: 30094626
Drug: Commonly recommended
Normalized name: Common carp
DrugBank: Common carp (DB10614)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commonly recommended dosing of omeprazole
Study: 30094626
Drug: Suboptimal dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suboptimal dosing of omeprazole
Study: 16732144
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone (2 mg/kg per day in three divided doses for 3 days)
Study: 18780503
Drug: Penehyclidine hydrochloride
Normalized name: Chlorpromazine Hydrochloride
DrugBank: Penequinine, Penehyclidine (DB16287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penehyclidine hydrochloride (0.01 mg/kg)
Study: 378017
Drug: Atropine (0.01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine (0.01 mg/kg)
Study: 18780503
Drug: Scopolamine (0.006
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scopolamine (0.006 mg/kg)
Study: 16038528
Drug: Midazolam +
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam + chemotherapy
Study: 16038528
Drug: Propofol +
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol + chemotherapy
Study: 16038528
Drug: Midazolam +
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam + chemotherapy and Propofol + chemotherapy
Study: 1823965
Drug: Induction therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction therapy based on melphalan
Study: 1823965
Drug: Chemotherapy supported
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy supported by immunomodulatory agents (calf thymus extract, levamisole, interferon)
Study: 8980592
Drug: Chloroquine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroquine (25 mg/kg over three days)
Study: 7036438
Drug: Fansidar (35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fansidar (35 mg sulphadoxin (+ 1/20 pyrimethamine) per kg single dose)
Study: 30982782
Drug: Acupressure applied
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acupressure applied to acupuncture points (PC‐6, HT‐7, CV‐17), twice per day (2-4 sessions)
Study: 26799154
Drug: Implant-assisted mandibular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implant-assisted mandibular removable partial dentures
Study: 23390192
Drug: EPA (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPA (1000 mg EPA:200 mg DHA)
Study: 23390192
Drug: DHA (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA (200 mg EPA:1000 mg DHA)
Study: 12716332
Drug: Powered toothbrush
Normalized name: Pro Clean Spinbrush Powered Toothbrush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Powered toothbrush (PTB) with brushing force of 75 g for 30, 60, 120, and 180 seconds
Study: 12716332
Drug: Powered toothbrush
Normalized name: Pro Clean Spinbrush Powered Toothbrush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Powered toothbrush (PTB) with brushing force of 150 g for 30, 60, 120, and 180 seconds
Study: 12716332
Drug: Powered toothbrush
Normalized name: Pro Clean Spinbrush Powered Toothbrush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Powered toothbrush (PTB) with brushing force of 225 g for 30, 60, 120, and 180 seconds
Study: 12716332
Drug: Powered toothbrush
Normalized name: Pro Clean Spinbrush Powered Toothbrush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Powered toothbrush (PTB) with brushing force of 300 g for 30, 60, 120, and 180 seconds
Study: 12716332
Drug: Brushing time
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brushing time of 120 seconds with forces in excess of 150 g
Study: 10938215
Drug: Transdermal nicotine
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal nicotine patch (used for the first 35 days)
Study: 10938215
Drug: Transdermal nicotine
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal nicotine patch (removed after 35 days)
Study: 10938215
Drug: Transdermal nicotine
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal nicotine patch (for females)
Study: 1345900
Drug: Broxaterol (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Broxaterol (0.5 mg three times a day for seven days)
Study: 28777755
Drug: ADS-5102 (amantadine)
Normalized name: Stahist AD
DrugBank: Chlorcyclizine (DB08936)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ADS-5102 (amantadine) 274 mg once daily at bedtime